GeoVax to Showcase Mpox Vaccine Progress at Emerging Growth Conference
TL;DR
GeoVax Labs' upcoming presentation on GEO-MVA could offer investors a unique advantage by highlighting potential regulatory acceleration and market positioning in vaccine development.
GeoVax will detail its GEO-MVA vaccine's development progress, including EMA's favorable Scientific Advice and its impact on the regulatory approval timeline.
GeoVax's advancements in Mpox and smallpox vaccines aim to enhance global health security and preparedness, making a safer tomorrow possible.
Discover how GeoVax's innovative MVA platform is revolutionizing vaccine development and manufacturing, promising a leap forward in pandemic readiness.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on August 20, 2025. The presentation will focus on the company's GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, and its development program. David Dodd, Chairman and CEO of GeoVax, will provide insights into the vaccine's progress and upcoming milestones, including the recent favorable Scientific Advice from the European Medicines Agency (EMA) that could expedite the regulatory approval process.
The GEO-MVA vaccine is designed to enhance global preparedness and stockpile strategies against Mpox and smallpox. GeoVax's MVA platform and U.S.-based manufacturing capabilities are poised to address critical needs in vaccine supply diversification, pandemic readiness, and biosecurity. The company's innovative approach could significantly contribute to the global effort to combat infectious diseases.
Interested parties can register to attend the conference and receive updates by visiting https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=govx. Questions can be submitted in advance or asked live during the presentation, with a replay available post-event on www.EmergingGrowth.com and the Emerging Growth YouTube channel.
GeoVax's participation in the Emerging Growth Conference underscores the importance of its work in developing vaccines for infectious diseases and cancer. The company's advancements in vaccine technology and regulatory progress highlight its potential to make a significant impact on public health and global biosecurity efforts.
Curated from NewMediaWire
